Chaigui Longmu Ejiao Paste for Ischemic Heart Disease

Inclusion Criteria: 1. Age 18-75 years, both sexes eligible; 2. Meets the diagnostic criteria for stable angina pectoris in ischemic heart disease (IHD), with stable condition for ≥4 weeks; 3. Has received standard Western medical treatment (including but not limited to antiplatelet agents, lipid-modifying/stabilizing plaque therapy, β-blockers, etc.) for at least 4 weeks, with stable dosages; 4. Meets the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria of "thoracic yang deficiency with heart vessel stasis" (or "chest yang insufficiency with heart meridian blood stasis"), with primary symptoms: chest oppression/pain, palpitations; at least 2 secondary symptoms: insomnia, aversion to cold, spontaneous sweating, irritability or restlessness; supported by tongue and pulse findings; 5. Has signed the informed consent form and is willing to participate voluntarily in the study. Exclusion Criteria: 1. Acute coronary syndrome or patients requiring emergency revascularization; 2. Use of traditional Chinese medicine (TCM) or Chinese patent medicines with therapeutic effects on ischemic heart disease within the past 2 weeks; 3. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg after treatment); 4. Severe heart failure (NYHA functional class IV), uncontrolled malignant arrhythmias, cardiogenic shock; severe cerebrovascular diseases; active or recurrent digestive system ulcers or other diseases with bleeding risk; other severe digestive system diseases; complicated with malignant tumors, hematological disorders, or other severe or progressive systemic diseases; complicated with other mental disorders that render the patient unable or unwilling to cooperate; 5. Severe hepatic or renal impairment (ALT/AST \> 3 × upper limit of normal, or creatinine \> 1.5 × upper limit of normal); 6. Known allergy to any component of the study formula; 7. Women who are pregnant, lactating, or planning pregnancy; 8. Patients who have participated in other clinical trials within the past 3 months; 9. Patients deemed by the investigator to be unsuitable for participation in the clinical trial.